Fermagate

Summary

Fermagate (CHEMBL4297751) is a phase-3 clinical-stage unknown; indicated across 1 condition including chronic kidney disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297751
Name	Fermagate
Type	Unknown
Max phase	3

Also known as: Alpharen, Fermagate, Fermagato, FERMAGATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic kidney disease	3	MONDO:0005300	MONDO:0024327

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00844662	PHASE3	TERMINATED	Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride
NCT00317694	PHASE2	COMPLETED	Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients
NCT00358722	PHASE2	TERMINATED	An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate
NCT00436683	PHASE2	COMPLETED	Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).